Thalidomide plus dexamethasone may become the treatment of choice for myeloma patients with low tumor mass, according to the results of a study published in the Jan. 1 issue of the Journal of Clinical Oncology. Investigators found that this combination performed better than did thalidomide alone.
“Based on our prior experience in patients with resistant disease, we postulated that the combination of thalidomide-dexamethasone would induce rapid reduction of tumor mass, allowing prompt collection of autologous blood stem cells with granulocyte-colony-stimulating factor alone,” write Donna Weber, MD, and colleagues from the University of Texas M.D. Anderson Cancer Center in Houston. “Although the mechanism of action of thalidomide remains unclear and may be related to antiangiogenic or direct antitumor effects against myeloma, the drug is effective despite resistance to multiple standard therapies.”
תגובות רוצה להצטרף לדיון?
יש להתחבר כדי להגיב.
התחבראין תגובות עדיין. היה הראשון להגיב!